Ad
related to: rna interference
Search results
Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks
Investor's Business Daily· 1 year agoIf there's one overarching theme that investors in biotech stocks should pay attention to in 2023,...
Insider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc
GuruFocus.com via Yahoo Finance· 8 months agoOn September 18, 2023, Christopher Anzalone, the CEO of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR),...
Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today
Motley Fool· 2 years agoShares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market...
Insider Sell: EVP, CLO & Secretary Indrani Franchini Sells 1,591 Shares of Alnylam ...
GuruFocus.com via Yahoo Finance· 4 months agoAlnylam Pharmaceuticals Inc (NASDAQ:ALNY), a biopharmaceutical company, focuses on the discovery,...
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 months agoStrengths: Pioneering RNAi therapeutics with a robust product portfolio and strategic...
Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars
Benzinga via Yahoo Finance· 1 year agoArrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced interim results from an ongoing Phase 1/2...
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Benzinga via Yahoo Finance· 1 year agoArrowhead Pharmaceuticals Inc (NASDAQ: ARWR) received written notice from Janssen, a unit of Johnson...
US FDA approves Novo Nordisk's therapy for rare genetic condition
Reuters via Yahoo News· 8 months agoThe once-monthly injection, to be sold under the brand name Rivfloza, is approved for use in people...
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Motley Fool· 1 year agoWhat happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were...
Arrowhead Pharmaceuticals Inc Insider Sells Shares
GuruFocus.com via Yahoo Finance· 5 months agoChief Discovery/Trans Medicine James Hamilton of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) sold 38,443 shares of the company's stock on January 5,...
